Potassium

Potassium

SCHEMBL4063307

NS(=O)(=O)CCc1ccccn1.[K]

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH1 P35367 2/20 0.55
ALDH1A1 P00352 4/20 0.51
NPC1 O15118 1/20 0.51
RAB9A P51151 1/20 0.51
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
NPSR1 Q6W5P4 2/20 0.50
LMNA P02545 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
POLB P06746 1/20 0.50
HRH3 Q9Y5N1 1/20 0.46
TAAR1 Q96RJ0 1/20 0.44
ALOX15 P16050 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CYP1A2 P05177 1/20 0.43
PRMT1 Q99873 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4184428 0.98 HRH1 (0.57) HRH1ALDH1A1NPC1RAB9AKMT2A
SCHEMBL4063300 0.96 HRH1 (0.55) HRH1ALDH1A1NPC1RAB9AKMT2A
SCHEMBL4249546 0.87 HRH1 (0.56) HRH1ALDH1A1NPC1RAB9AKMT2A
SCHEMBL4131768 0.79 ALDH1A1 (0.53) HRH1ALDH1A1NPC1RAB9AKMT2A
SCHEMBL1272589 0.79 LMNA (0.60) HRH1ALDH1A1NPC1RAB9AKMT2A
SCHEMBL1272587 0.79 ALDH1A1 (0.53) HRH1ALDH1A1NPC1RAB9AKMT2A
SCHEMBL497367 0.79 LMNA (0.60) HRH1ALDH1A1NPC1RAB9AKMT2A
SCHEMBL51377 0.79 HRH1 (0.50) HRH1KMT2ALMNATDP1CA1
SCHEMBL29596510 0.79 HRH1 (0.50) HRH1KMT2ALMNATDP1CA1
Potassium Ion SCHEMBL9065490 0.78 ALDH1A1 (0.55) HRH1ALDH1A1NPC1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1322624-B1 ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY ACTELION PHARMACEUTICALS LTD (CH) 2009-10-21 EP disclosed
US-7091201-B2 Arylalkane-sulfonamides having endothelin-antagonist activity ACTELION PHARMACEUTICALS LTD. (CH) 2006-08-15 US disclosed
US-20040102464-A1 Arylalkane-sulfonamides having endothelin-antagonist activity ACTELION PHARMACEUTICALS LTD. (CH) 2004-05-27 US disclosed
EP-1322624-A1 ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY Actelion Pharmaceuticals Ltd. (CH) 2003-07-02 EP disclosed
WO-2002024665-A1 ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY ACTELION PHARMACEUTICALS LTD (CH) 2002-03-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040102464-A1 Arylalkane-sulfonamides having endothelin-antagonist activity EDNRA, EDNRB, ECE2 HRH1 185/4885ALDH1A1 2214/4885NPC1 2574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.